Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight

DelveInsight projects the oncolytic virus cancer therapy market at USD 177 million in the 7MM in 2025, with growth supported by a widening genetically engineered viral pipeline and expanding clinical trials across major cancer types. The report highlights therapies in advanced development and regulatory momentum (e.g., FDA accelerated approval for RP1/vusolimogene oderparepvec-wtpg plus nivolumab in unresectable advanced cutaneous melanoma; FDA IND clearance for UGN-501), supporting a constructive medium-term outlook for the sector.

Analysis

The investable signal is not that this becomes a large category; it is that capital will likely concentrate in the few assets that can plausibly clear regulatory and commercial friction. In practice, that favors late-stage, label-near names with a repeatable administration workflow and enough differentiation to earn reimbursement without heavy discounting. The biggest second-order winner is the antibody backbone ecosystem: checkpoint partners may get a small duration extension in narrow salvage settings, but the real economic upside sits with the virus platforms that can keep their safety profile clean enough to avoid falling back into the "interesting science, poor utilization" bucket.

For the broader basket, the market is likely to overestimate revenue scale and underestimate launch friction. These therapies are procedure-heavy, local, and indication-specific, so uptake should behave more like a slow specialty rollout than a binary biotech hockey stick; that means the first 1-3 months are mostly sentiment and headline beta, while the 6-18 month outcome depends on durability, site-of-care adoption, and whether payers view the treatment as additive or substitutive. If the first commercial scripts disappoint or post-approval data look less durable than the cross-sectional pipeline narrative implies, multiple compression can be severe because the addressable universe is still too small to support many winners.

Contrarian view: the market report is directionally bullish but probably too optimistic on breadth. A tiny category with a long list of programs usually means optionality, not franchise value; most names will need successive financings before they ever see meaningful revenue contribution, which makes dilution the real short thesis, not science failure alone. The thesis is falsified if CGON/REPL show rapid early adoption with durable response curves and clean safety in real-world use over the next 2-4 quarters; otherwise, the sector remains a trading vehicle, not a structural growth theme.

Key Decisions for Investors

• Long REPL vs. short a basket of early-stage viral names (ONCY, MBIO, PVCT) over the next 1-3 months: own the approved/near-approved commercialization path, fade programs that still need capital and data; target relative outperformance if launch metrics start to separate.
• Accumulate CGON on post-rally pullbacks into the next pivotal/filing catalyst window; use a 6-12 month horizon and size for binary trial/regulatory risk. Best risk/reward is if the market is discounting only approval and not initial adoption quality.
• Avoid chasing the broad basket on the report headline; if anything, short weaker balance-sheet names into strength when financing windows reopen. The cleanest expression is a relative-value short in the names most exposed to dilution, not an outright sector short.
• Watch URGN as an adjacent bladder-cancer read-through trade: if the bladder-treatment complex re-rates on clinical momentum, URGN can participate without needing the same valuation stretch as pure-play platform names. Falsifier: weak bladder adoption or no follow-through in urology channel checks.
• If you want optionality, use call spreads rather than outright longs in the higher-beta names (e.g., REPL or CGON) into the next 1-2 catalyst events. The upside is meaningful if adoption/data surprise, but implied vol and binary risk make naked calls poor risk-adjusted entries.